CL2008001560A1 - Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico. - Google Patents
Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico.Info
- Publication number
- CL2008001560A1 CL2008001560A1 CL2008001560A CL2008001560A CL2008001560A1 CL 2008001560 A1 CL2008001560 A1 CL 2008001560A1 CL 2008001560 A CL2008001560 A CL 2008001560A CL 2008001560 A CL2008001560 A CL 2008001560A CL 2008001560 A1 CL2008001560 A1 CL 2008001560A1
- Authority
- CL
- Chile
- Prior art keywords
- alzheimer
- treatment
- neurodegenerative diseases
- down syndrome
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Compuestos derivados de heterociclo de nitrógeno y oxígeno; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades neurodegenerativas, como Alzheimer, síndrome de Down; kit farmacéutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94140507P | 2007-06-01 | 2007-06-01 | |
US98448407P | 2007-11-01 | 2007-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008001560A1 true CL2008001560A1 (es) | 2009-05-22 |
Family
ID=40084164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001560A CL2008001560A1 (es) | 2007-06-01 | 2008-05-29 | Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico. |
Country Status (18)
Country | Link |
---|---|
US (1) | US8426403B2 (es) |
EP (1) | EP2152695A2 (es) |
JP (1) | JP5495331B2 (es) |
KR (1) | KR20100037053A (es) |
CN (1) | CN101809016A (es) |
AR (1) | AR066152A1 (es) |
AU (1) | AU2008263207B2 (es) |
BR (1) | BRPI0812170A8 (es) |
CA (1) | CA2689948A1 (es) |
CL (1) | CL2008001560A1 (es) |
CO (1) | CO6241123A2 (es) |
EC (1) | ECSP099776A (es) |
IL (1) | IL202315A0 (es) |
MX (1) | MX2009013131A (es) |
PE (1) | PE20090363A1 (es) |
RU (1) | RU2009148866A (es) |
TW (1) | TW200914459A (es) |
WO (1) | WO2008153793A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008097538A1 (en) * | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Therapeutic agents |
JP2012508182A (ja) * | 2008-11-06 | 2012-04-05 | シェーリング コーポレイション | γ−セクレターゼ調節剤 |
AU2009314205A1 (en) * | 2008-11-13 | 2010-05-20 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
JP5503663B2 (ja) | 2008-11-13 | 2014-05-28 | メルク・シャープ・アンド・ドーム・コーポレーション | ガンマセクレターゼモジュレータ |
AR074702A1 (es) * | 2008-12-22 | 2011-02-02 | Schering Corp | Moduladores de gamma secretasa y composiciones farmaceuticas que los contienen |
WO2010147969A2 (en) * | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
WO2010147973A1 (en) * | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
EP2443119A1 (en) * | 2009-06-16 | 2012-04-25 | Schering Corporation | Gamma secretase modulators |
JP2014001142A (ja) * | 2010-10-05 | 2014-01-09 | Astellas Pharma Inc | シクロアルカン化合物 |
EP2691393B1 (en) | 2011-03-31 | 2016-09-14 | Pfizer Inc | Novel bicyclic pyridinones |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
US9598437B2 (en) | 2013-12-04 | 2017-03-21 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
EP3253755B1 (en) | 2015-02-03 | 2020-08-26 | Pfizer Inc | Novel cyclopropabenzofuranyl pyridopyrazinediones |
WO2018226992A1 (en) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Tau aggregation inhibitors |
EP3668886A2 (en) | 2017-08-18 | 2020-06-24 | Adrx, Inc. | Tau aggregation peptide inhibitors |
KR20200127177A (ko) * | 2018-02-28 | 2020-11-10 | 니뽄 다바코 산교 가부시키가이샤 | 포화 환 축합 디히드로피리미디논 또는 디히드로트리아지논 화합물 및 그의 의약 용도 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1065324A (en) | 1974-05-13 | 1979-10-30 | E.R. Squibb And Sons | 2-aminoalkyl-3,3a,4,5,6,7-hexahydro-3-phenyl-7-(phenylmethylene)-2h-indazoles and related cyclohepta (c) pyrazoles and cyclopentapyrazoles |
CH594667A5 (en) | 1974-05-31 | 1978-01-13 | Squibb & Sons Inc | Hexahydro-2H-pyrazolo(4,3-C) pyridine derivs |
US3979381A (en) | 1975-08-11 | 1976-09-07 | E. R. Squibb & Sons, Inc. | Thiopyrano[4,3-c] pyrazoles |
US4003890A (en) | 1976-05-27 | 1977-01-18 | E. R. Squibb & Sons, Inc. | Benzylidene pyrano[4,3-c]pyrazoles |
US4065617A (en) | 1977-02-04 | 1977-12-27 | E. R. Squibb & Sons, Inc. | 2-(2,2,2,-Trifluoroethyl)-3,3a,4,5,6,7-hexahydro-2H-pyrazolo[4,3-c]pyridines |
EP1066279A4 (en) * | 1998-03-25 | 2004-09-08 | Bristol Myers Squibb Co | ANOREECTIC IMIDAZOLONE COMPOUNDS: II. phenyl derivatives |
ES2220753T3 (es) * | 2000-03-20 | 2004-12-16 | N-Gene Research Laboratories Inc. | Derivados de amidoxina del acido propencarboxilico, procedimiento para su preparacion, y composiciones farmaceuticas que los contienen. |
WO2004071431A2 (en) | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
JP4847868B2 (ja) | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | 化合物、及び、アミロイドベータの調節におけるその使用 |
JP2007528857A (ja) | 2003-07-11 | 2007-10-18 | ミリアド ジェネティクス, インコーポレイテッド | アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態 |
US20070293538A1 (en) | 2004-04-13 | 2007-12-20 | Myriad Genetics, Incorporated | Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders |
WO2005110422A2 (en) | 2004-05-19 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Treatment of diseases associated with altered level of amyloid beta peptides |
WO2005115990A1 (ja) | 2004-05-26 | 2005-12-08 | Eisai R & D Management Co., Ltd. | シンナミド化合物 |
EP1650183A1 (en) | 2004-10-21 | 2006-04-26 | Cellzome Ag | (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy |
TWI386207B (zh) * | 2005-11-24 | 2013-02-21 | Eisai R&D Man Co Ltd | 味啉類型之肉桂醯胺化合物 |
TWI370130B (en) * | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
KR101464651B1 (ko) * | 2006-03-09 | 2014-11-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 다환식 신나미드 유도체 |
EP2155737A1 (en) | 2007-05-07 | 2010-02-24 | Schering Corporation | Gamma secretase modulators |
BRPI0812491A2 (pt) | 2007-06-01 | 2014-12-02 | Schering Corp | Moduladores de gama secretase |
JP5503663B2 (ja) | 2008-11-13 | 2014-05-28 | メルク・シャープ・アンド・ドーム・コーポレーション | ガンマセクレターゼモジュレータ |
-
2008
- 2008-05-28 KR KR1020097027345A patent/KR20100037053A/ko not_active Application Discontinuation
- 2008-05-28 CN CN200880100987A patent/CN101809016A/zh active Pending
- 2008-05-28 MX MX2009013131A patent/MX2009013131A/es not_active Application Discontinuation
- 2008-05-28 WO PCT/US2008/006734 patent/WO2008153793A2/en active Application Filing
- 2008-05-28 US US12/601,322 patent/US8426403B2/en active Active
- 2008-05-28 EP EP08767902A patent/EP2152695A2/en not_active Withdrawn
- 2008-05-28 CA CA2689948A patent/CA2689948A1/en not_active Abandoned
- 2008-05-28 AU AU2008263207A patent/AU2008263207B2/en not_active Ceased
- 2008-05-28 RU RU2009148866/04A patent/RU2009148866A/ru not_active Application Discontinuation
- 2008-05-28 JP JP2010510316A patent/JP5495331B2/ja not_active Expired - Fee Related
- 2008-05-28 BR BRPI0812170A patent/BRPI0812170A8/pt not_active IP Right Cessation
- 2008-05-29 AR ARP080102261A patent/AR066152A1/es not_active Application Discontinuation
- 2008-05-29 PE PE2008000920A patent/PE20090363A1/es not_active Application Discontinuation
- 2008-05-29 TW TW097119930A patent/TW200914459A/zh unknown
- 2008-05-29 CL CL2008001560A patent/CL2008001560A1/es unknown
-
2009
- 2009-11-24 IL IL202315A patent/IL202315A0/en unknown
- 2009-12-01 EC EC2009009776A patent/ECSP099776A/es unknown
- 2009-12-01 CO CO09137086A patent/CO6241123A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2008153793A2 (en) | 2008-12-18 |
IL202315A0 (en) | 2010-06-30 |
BRPI0812170A8 (pt) | 2016-02-10 |
EP2152695A2 (en) | 2010-02-17 |
US20100256128A1 (en) | 2010-10-07 |
CN101809016A (zh) | 2010-08-18 |
CA2689948A1 (en) | 2008-12-18 |
WO2008153793A3 (en) | 2009-03-19 |
AU2008263207B2 (en) | 2013-10-03 |
CO6241123A2 (es) | 2011-01-20 |
AR066152A1 (es) | 2009-07-29 |
BRPI0812170A2 (pt) | 2014-12-02 |
US8426403B2 (en) | 2013-04-23 |
MX2009013131A (es) | 2010-01-15 |
RU2009148866A (ru) | 2011-07-20 |
AU2008263207A1 (en) | 2008-12-18 |
AU2008263207A2 (en) | 2010-01-28 |
KR20100037053A (ko) | 2010-04-08 |
ECSP099776A (es) | 2010-01-29 |
PE20090363A1 (es) | 2009-04-01 |
JP2010529015A (ja) | 2010-08-26 |
JP5495331B2 (ja) | 2014-05-21 |
TW200914459A (en) | 2009-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008001560A1 (es) | Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico. | |
CL2008003593A1 (es) | Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer | |
CL2008001303A1 (es) | Compuestos derivados de heterociclos, moduladores de gamma secretasa; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento del alzheimer. | |
CL2008001914A1 (es) | Compuestos heterociclicos de nitrogeno y oxigeno,moduladores de gama secretasa, composicion farmaceutica de dichos compuestos; kit farmaceutico y su uso para prevenir o tratar enfermedades asociadas al sistema nervioso central como alzheimer, sindrome de down, enfermedades neurodegenerativas, inhibir el deposito de proteina amiloide. | |
CL2008001721A1 (es) | Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales. | |
UY30759A1 (es) | Compuestos quimicos | |
AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
CL2008001114A1 (es) | Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras. | |
ECSP078013A (es) | Inhibidores heterocíclicos de mek y métodos de uso de ellos | |
AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
CL2009000619A1 (es) | Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer. | |
CL2008002049A1 (es) | Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
CL2009000119A1 (es) | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. | |
CL2008002809A1 (es) | Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros. | |
UY31141A1 (es) | Compuestos de piperidina y sus usos |